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Abstract
Background: To discuss the meaning of serum oestradiol monitoring in frozen embryo transfer
cycle using hormone replacement without pretreatment with gonadotropin hormone (GnRH)
agonist.
Methods: The data from two hundred twelve women undergoing two hundred seventy-four
frozen-thawed embryo transfer (FET) cycles was included in this retrospective cohort study. They
were detected of serum oestradiol levels and endometrium thicknesses during hormone
supplement FET cycles and compared their pregnancy outcomes according to their oestradiol level
on progesterone initiation day.
Results: Patients with different levels of serum oestradiol (percentile 0–25th, 25th–75th and 75th–
100th) on progesterone initiation day yielded the endometrium thickness of 9.3 ± 0.12, 8.9 ± 0.07
and 9.1 ± 0.11 mm(P > 0.05) and the pregnancy rate of 32.2%, 38.4% and 36.3% (P > 0.05)
respectively.
Conclusion: The serum estradiol level did not predict pregnancy success in hormone replacement
FET cycles, suggesting that oestradiol monitoring in this method of endometrial preparation is
unnecessary.
Background
In in vitro fertilization treatment, the transfer of frozen
embryos has been a good option to improve accumulated
pregnancy rate and avoid ovarian hyperstimulation syn-
drome (OHSS). Frozen embryo transfer in women with
functioning ovaries can be timed with ovulation in natu-
ral cycle or after artificially preparing the endometrium
with exogenous hormones. Although natural cycle proto-
col was often preferred by many patients for afraid of hor-
mones' side effect, problems often occur when this
protocol is used. The accurate monitoring of the cycle
required to determine ovulation entails higher costs of
money and time. The exact timing of ovulation is often
difficult to determine, particularly in women with irregu-
lar cycle or poor follicle development, so the risk of cycle
cancellation is therefore high.
Published: 4 July 2008
Journal of Experimental & Clinical Assisted Reproduction 2008, 5:4 doi:10.1186/1743-1050-5-
4
Received: 19 May 2008
Accepted: 4 July 2008
This article is available from: http://www.jexpclinassistreprod.com/content/5/1/4
© 2008 Niu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Assisted Reproduction 2008, 5:4 http://www.jexpclinassistreprod.com/content/5/1/4
Page 2 of 5
(page number not for citation purposes)
Artificial endometrial preparation with exogenous ster-
oids has some important advantages. Doctors and
patients can select the timing of embryo thawing and
transfer, and the possibility of cycle cancellation can be
drastically reduced. Many published articles have proved
the same as or higher pregnancy rate of hormone replace-
ment cycle than natural cycle [1,2]. There are two sorts of
artificial endometrial preparation: using GnRH agonist to
obtain a previous ovarian suppression or not. The aim of
pretreatment with GnRHa is to avoid spontaneous ovula-
tion, but it is costly and there is a risk of hypoestrogenic
side effect that would lengthen the preparation. Many
published studies compared the two artificial protocols
and showed the similar clinical outcome [2-5]. Therefore,
clearly the program of absent of GnRH agonist was more
preferred because of its simple and low cost.
It has been known that in stimulation cycle, concentration
of serum E2 had important roles in regulation gonadotro-
pin doses and prediction of outcomes. In hormone
replacement FET cycle without pituitary, exogenous estro-
diol would lead to a rise in serum E2, similar to that
observed before ovulation. Whether the hormone's level
have any meaning in deciding the timing of ET or predict-
ing the possibility of pregnancy? To date, few articles have
reported the question. The present retrospective study was
tending to discuss the meaning of E2 concentration in fro-
zen embryo transfer cycle using hormone replacement
without GnRHa.
Methods
Patients
From January 2004 until July 2007, all the patients who
underwent the transfer of their frozen-thawed embryos
that were cryopreservated in previous IVF or ICSI cycle
and preferred hormone replacement protocol were
included in this retrospective study. The study group con-
sisted of 136 women with functioning ovaries who under-
went 176 cycles of frozen-thawed ET. 33 of the patients
hadn't fresh embryo transfer for avoiding OHSS. There
were 155 ovulatory and 57 anovulatory patients in the
group and they all preferred artificial endometrial prepa-
ration for lower cancellation rate.
Embryo freezing-thawing
On the 3rd day after oocyte retrival, fresh cleavage-stage
embryos generated using IVF or ICSI were assessed and
assigned using a standardized scoring system: A) number
of blastomeres (BL) was divided into four categories: 1 =
four BL, 2 = five BL, 3 = six to seven BL and 4 = eight to ten
BL. B) Degree of fragmentation (FR) was also scaled with
a score of 4 indicating no fragmentation, 3 representing ≥
10%, 2 means 11–25%, 1 indicating 26 – 50%, and 0
refers to > 50%; and C) Equality (EQ) or variation in the
sizes of BL was categorized as 1, uniform or almost uni-
form BL size or 0, varying BL size. The total score for an
embryo included the three aspects (BL, FR, and EQ). If the
score for an embryo reached 5, it was considered "a viable
embryo". Only those viable embryos were selected to be
cryopreservated according to a protocol previously
described using 1,2-propanediol and sucrose solution in
phosphate-buffered saline as cryoprotectants[6]. Thawing
was preformed by the transfer of cryotubes into a warm
bath at a temperature of 35°C. After complete thawing,
the embryos were processed through a series of decreasing
concentrations of propanedion and sucrose, washed 3
times in phosphate-buffered saline, and placed in fresh
equilibrated, warmed culture medium. Embryos surviving
the freezing procedure (≥ 50% of their initial number of
blastomeres intact) were then transferred with 1 hour.
Intrauterine transfer of thawed embryos was scheduled
after artificial endometrial preparation.
Endometrial preparation and ET
All patients started estrogen valerianic (progynova®,
Schering, German) treatment on the 2nd day of their men-
strual period without previous down regulation of gona-
dotropin. The standard E replacement was 2 mg pre day,
5 days and 3 mg per day, 5 days. 10 days later, patients'
endometrial thickness was evaluated through vaginal
ultrasound. If the thickness was ≥ 8 mm, the same dose of
estrogen was continued for another 4 days and if not, the
doses increased to 4 to 6 mg/d, given per os in 2 divided
doses for another 10 days by step-up. On the day of thick-
ness reaching 8 mm, progesterone was injected 40 mg/d,
2 days and changed to 40 mg, bid.
If the endometrium didn't reach the thickness of 8 mm
after 20 days of continuous E administration, the cycle
was canceled. Embryos were transferred after 72 h after
the initiation of progesterone. The same doses of eatrogen
and progesterone were continued until obtaining a serum
β-hCG assay 11 days after ET. If the pregnancy test was
positive, the hormone replacement went on another 8
weeks and patients were followed with serial ultrasonog-
raphy to determine fetal viability. Clinical pregnancy was
defined as the presence of a gestational sac on trans-
verginal ultrasound.
Hormone assay
Serum level of FSH (IU/L), LH (IU/L), E2 (pg/ml) and P
(ng/ml) were measured in all patients on the day of E ini-
tiation (day 2), LH and E2 levels were measured on the
days ultrasound was done, the day of P administration
and the day of ET. Blood was drawn at 8 AM, 10 hours
after the last doses of hormone. Hormone assay was per-
formed by commercially available kits with use of Fluores-
cence Polariza immunassay (FIPA). by the Abbott
AXSYM® assay(Abbott Labs, Abbott Park, IL, USA). TheJournal of Experimental & Clinical Assisted Reproduction 2008, 5:4 http://www.jexpclinassistreprod.com/content/5/1/4
Page 3 of 5
(page number not for citation purposes)
inter- and intra-assay coefficients of variation were all
<10%.
Statistical Analysis
Statistical Package for Social Sciences (SPSS v 13.0 for win-
dows, Chicago, IL) software was used for data analysis.
Descriptive statistics were performed for each variable;
quantitative results are presented as the mean (± SD).
Means were compared by using one way ANOVA and two-
sample t-test. Proportions for the two groups were com-
pared by using the χ2 test and the Fisher exact test. P < 0.05
was considered statistically significant.
Result
Between January 2004 and October 2007, 212 patients
underwent 274 artificially prepared frozen embryo trans-
fer without prior pituitary desensitization using GnRHa
and all embryos available for transfer originated from the
same fresh cycle. Mean age of the patients in fresh cycle
and frozen embryo transfer were 29.3 ± and 30.1 ± respec-
tively, mean duration of embryos cryopreservation before
being thawed and transferred were 7.3 ± 3.5 months. In
frozen embryo transfer cycle, the mean days of exogenous
E2 supplementation before progesterone administration
were 18.3 ± 2.9 and the mean endometrium thickness on
progesterone initial day was 8.5 ± 0.3 mm. The serum LH
and E2 concentration on progesterone day was 13.5 ± 2.8
IU/ml and 197.2 ± 65.5 pg/ml respectively. The averange
number of embryo transferred was 2.5 ± 0.3 and the total
clinic pregnancy was 41.2%.
To discuss whether different levels of E2 would result in
different outcomes, patients were classified according to
serum E2 concentrations percentile (group 1: 0–25th,
group 2: 25th–75th and group 3: 75th–100th) on the day of
progesterone injection. The frozen embryos had been
originated from some stimulation cycle. Table 1 details
the patients' characteristic of each group in stimulation
cycles. There were no differences in age, basal FSH, total
gonadotrophin doses, No. of oocytes retrieved, fertiliza-
tion rate and No. of embryos frozen between groups.
Table 2 listed the characteristic of groups in frozen-thawed
embryo transfer cycle. All of the indicators were similar
between groups, including duration of embryo cryop-
reservation and estrogen administration, embryo survival
rate and No., score of embryo transferred and clinical out-
comes. Table 3 compares the patients' E2 levels and
endometrium thickness on day 2, day12 and the day of
progesterone initiation. The hormone levels of the three
groups show differences from day12 and although the
varieties of E2 level, their endometrium had the same
thickness.
Discussion
The success of a frozen-thawed embryo transfer program
is closely linked to exact synchronization between
endometrial maturation and embryo development [7].
Such synchronization may be achieved in a natural cycle
after spontaneous ovulation [7,8] or after artificial prepa-
ration of the endometrium with exogenous steroids [8,9].
In artificial endometrium preparation cycle without sup-
pression by GnRH agonist, it's very important to start
estradio treatment in the early follicular phase (on day 1
or day 2) in order to inhibit spontaneous ovulation.
Although high fixed doses of estradiol and step-up proto-
col had the likely effect, we choose the latter considering
that more physiologic estrogenic stimulation of
endometrium that mimics the hormonal pattern of spon-
taneous cycle is more suitable for endometrial develop-
ment. In this type of endometrium preparation program,
endometrium thickness is the key to be monitored. A
receptive endometrium should reach a thickness of at
least 5–8 mm [10]. Above this threshold, the
endometrium can maintain its receptivity for up to 40–60
days, as has been shown by oocyte donation programs.
Navot et al [11] reported that shorter (5–10 days) and
lower dosage protocols of estradiol priming of the
endometrium could result in higher abortion rates. Borini
et al also found in a proliferative phase of less than 10
days are related to a higher abortion rate [12]. This indi-
cates an optimal endometrial proliferation which is neces-
sary to enable optimal development of progesterone
receptors and subsequent transformation into an
Table 1: Patients and stimulation cycle characteristic categorized according to percentile analysis of E2 levels measured on P initiation 
day
Groups of cycles according to E2 level percentile p
Group1 (n = 55) Group 2 (n = 135) Group 3 (n = 84)
Age at stimulation(years) 30.7 ± 3.7 29.9 ± 3.9 30.1 ± 3.5 NS
Basal serum FSH level(IU/L) 5.9 ± 2.8 6.3 ± 2.5 5.8 ± 2.3 NS
Total Gn doses(IU) 26.3 ± 7.5 27.0 ± 8.3 26.5 ± 7.8 NS
No. of oocyte retrieved 18.1 ± 8.1 18.9 ± 8.6 17.3 ± 7.8 NS
No. of oocytes fertilized normally 13 ± 5.2 14.6 ± 5.8 13.2 ± 5.5 NS
No. of embryos frozen/cycle 5.7 ± 2.1 6.8 ± 2.6 6.5 ± 2.3 NSJournal of Experimental & Clinical Assisted Reproduction 2008, 5:4 http://www.jexpclinassistreprod.com/content/5/1/4
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endometrium receptive to the transferred embryo. Dev-
roey and Pados [13] presumed that an adequate period of
estrogen administration is necessary in order to achieve a
subsequent normal secretory endometrium. In our pro-
gram, as a step-up protocol, we usually controlled the
duration of proliferative phase in 15–21 days, even the
thickness had reached 8 mm before that time.
The present retrospective study addressed the question
whether different levels of E2 on progesterone initial day
are associated with the likelihood of outcomes, in patients
undergoing a FET cycle in which endometrium is prepared
with hormone replacement in the absence of pituitary
down regulation. The data presented herein show that
when given enough duration of estradiol administration,
different E2 levels on progesterone initial day yielded the
similar pregnancy and implantation rate. On the other
hand, the thickness of endometrium had not relationship
with E2 concentration. The information might be useful in
clinical practice since it indicates that a wide range of E2
levels is compatible with establishment of clinical preg-
nancy, and thus there is no value in measuring E2 levels
during a FET cycle. Our findings also corroborate observa-
tions by other investigators. Remohi et al [10] suggested
in 1997 that neither endometrial thickness nor serum
estradiol were able to predict optimal receptivity and
therefore outcome in oocyte donation. From the experi-
ence of Simon et al [1], the serum E2 level was an unim-
portant index when the decision for ET had to be made,
and therefore only the measurement of endometrium
thickness by ultrasound was need. Banz et al [14] found
that endometrial thickness between 7 and 15 mm and
estradiol serum level did not relate to significantly differ-
ent pregnancy rates. So they concluded that monitoring is
unnecessary in cryopreservation cycles with a protocol
using estradiol patches and progesterone vaginal gel since
the percentage of the patients with an endometrial thick-
ness <7 mm or >15 mm was only 4.8%.
Remohi J et al [15] reported that in oocyte donation
cycles, serum oestradiol on centrations < 100 pg/ml are
able to induce changes sufficient to sustain normal
implantation, and when those cycles with serum oestra-
diol, 100 pg/ml were further explored, they found normal
implantation at concentrations,50 pg/ml, which in natu-
ral cycles is considered to be the limit for ovarian arrest.
The crucial role of steroid hormones in preparing and
maintaining the endometrium for successful embryonic
implantation is beyond any doubt. However, unlike pro-
Table 2: Patients' characteristic in FRET cycle categorized according to percentile analysis of E2 levels measured on P initiation day
Groups of cycles according to E2 level percentile p
Group1 (n = 55) Group 2 (n = 135) Group 3 (n = 84)
Duration between freezing and thawing(month) 8.0 ± 3.8 7.2 ± 3.0 7.7 ± 3.4 NS
Mean basal serum FSH level(IU/L) 5.2 ± 2.1 6.3 ± 2.4 5.8 ± 2.6 NS
Total estradiol doses(mg)a 44.8 ± 5.5 43.9 ± 5.8 44.2 ± 5.7 NS
Duration of estradiol supplementation 18.4 ± 2.3 18.8 ± 2.2 18.0 ± 2.1 NS
No. of embryos thawed/cycle 2.9 ± 0.5 3.3 ± 0.4 3.2 ± 0.5 NS
No. of embryos surviving/thawb 2.5 ± 0.3 2.6 ± 0.2 2.4 ± 0.4 NS
Post-thaw embryo survival rate(%) 86 82 89 NS
Endometrial thickness(mm)a 8.6 ± 0.1 8.3 ± 0.2 8.7 ± 0.3 NS
Embryo score(mean) 7.1 7.3 7.2 NS
Pregnancy rate(%) 44 40.8 41.9 NS
Implantation rate(%) 26.2 23.1 22.5 NS
On going pregnancy rate(%) 32.2 38.4 36.3 NS
a on the day of progesterone administration
b all the survival embryos were transferred in to uterus
Table 3: E2 levels and endometrium thickness categorized according to percentile analysis of E2 levels measured on P initiation day of 
an artificial endometrium preparation cycle for FRET
day E2 level(pg/ml) p Endometrium thickness(mm) p
Group 1 Group 2 Group 3 Group 1 Group 2 Group 3
Day2 43 ± 12.4 52 ± 15.5 50 ± 17.9 NS 5.5 ± 1.9 5.8 ± 2.0 5.7 ± 1.9 NS
Day12 90.4 ± 18.4 121.8 ± 23.5 156.4 ± 39.6 0.03 6.9 ± 0.18 6.7 ± 0.11 7.0 ± 0.14 NS
Day of P initiation 110 ± 20.5 191.9 ± 27.7 299 ± 48.9 < 0.01 9.3 ± 0.12 8.9 ± 0.07 9.1 ± 0.11 NSPublish with BioMed Central    and   every 
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gesterone, oestradiol requirements for implantation in
humans are very low. The majority of authors appear to
agree with the concept that oestradiol is permissive but
not essential in mammals that do not undergo dispause
[16-19]. Our clinical study suggestted the existence of a
wide oestradiol window which allows the endometrium
to prepare itself for implantation. According to Simon et
al [20], the oestradiol window reflected a permissive hor-
monal effect rather than a direct action performed at the
paracrine/autocrine concentration by cytokines and adhe-
sion molecules. This may be the reason for the absence of
a relationship between oestradiol concentrations and
implantation at the clinical concentration. The serum
estradiol level did not predict pregnancy success in hor-
mone replacement FET cycles, suggesting that oestradiol
monitoring in this method of endometrial preparation is
unnecessary."
In conclusion, our study suggest that in E2 step-up artifi-
cial endometrium preparation protocol without pituitary
down-regulation, assessment of E2 level on progesterone
initial day does not appear to yield useful information in
predicting pregnancy success. So, it is therefore possible
that our protocol can be further simplified by performing
only ultrasound tests and a single measurement of serum
P on the day of P initiation.
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